Sweden's EQT agreed to acquire Qiagen for €9.6 billion ($10.78 billion), valuing the molecular testing firm at $12.1 billion. The transaction is expected to close in mid-2027, leading Qiagen to suspen
reuters · 2026-10-21 14:47
EQT is in advanced talks to acquire Qiagen with a binding offer exceeding $50 per share. Private equity firms including KKR have also bid, while Qiagen's board evaluates the strategic options amidst a
reuters · 2026-10-20 11:55
Qiagen is reportedly attracting early takeover interest from major buyout firms including EQT, Advent, and KKR, according to Bloomberg News. However, Reuters stated it could not immediately verify the
reuters · 2026-07-09 08:04